Acorda Therapeutics (ACOR) Beats Q4 EPS Expectations; Revs Heavy
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.45, $0.27 better than the analyst estimate of $0.18. Revenue for the quarter came in at $72.64 million versus the consensus estimate of $69.16 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- NextPlat Corp (NXPL) Reports Q2 Loss of $0.05
- Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
